Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years

Anas M. Alsughayer, MD1; Tamara Z. Dabbagh, MSc1; Rashid H. Abdel-Razeq, MD1; Ghada N. Al-Jussani, MD2; Salam Alhassoon, MSc1; and Maher A. Sughayer, MD1

abstract

PURPOSE Estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2) are the mainstay of breast cancer management, and their prevalence rates vary among different populations possibly related to ethnic/genetic and/or socioeconomic status. In a previous study conducted at the King Hussein Cancer Center (published 2006), Jordan ER/PR/HER2 rates for patients diagnosed in 2003-2004 were 50.8%/57.5%/17.5%, respectively. The aim of this study is to revisit the prevalence rates to see if they have changed over the years with changing socioeconomic status.

MATERIALS AND METHODS We retrieved clinicopathologic data of all patients (1,185) diagnosed with breast cancer during 2018. The data included age, histologic type, grade, and ER/PR/HER2 status as determined by immunohistochemistry and/or fluorescence in situ hybridization for HER2.

RESULTS The mean age of patients was 52 (median = 51, range = 25-92) years, and the majority (73.2%) had invasive carcinoma of no special type. ER/PR/HER2 were 77.0%/72.4%./23.8%, respectively. Triple-negative breast cancers were 10.1%. In comparison with previous results of 2006, the changes are statistically significant. Similar changes were seen in other Middle Eastern populations. The current rates are close to those of Western populations.

CONCLUSION Rates of ER/PR/HER2 expression have significantly changed and are close to those of Western populations for ER/PR. We propose that such changes are secondary to the adoption of a westernized lifestyle and socioeconomic changes.

JCO Global Oncol 8:e2100359. © 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

INTRODUCTION

Breast cancer is the most common cancer in Jordan and the third leading cause of cancer death after lung and colorectal cancers. Similarly, breast malignancies are among the leading causes of cancer deaths among women globally.1,2

Breast cancer is a heterogeneous hormone-dependent tumor. The molecular mechanisms of this hormone dependence have been the focus of studies in the past few decades, primarily to understand the predictive role and prognostic value of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in breast cancer management. This is because many breast cancers rely on ER and/or PR for growth, and this effect requires the presence of ER-expressing/PR-expressing cells. Binding of ER and/or PR hormone to its receptor results in unmasking of the DNA-binding sites on the receptor, migration into the nucleus, and binding to specific estrogen response elements near the genes responsible for the physiologic actions of the hormone.3,4,6

ER−(estrogen receptor-negative)/PR−(progesterone receptor-negative) tumors tend to be diagnosed at later stages and show aggressive pathologic features (eg, high nuclear grade, poor histologic differentiation, and high proliferative index).3 It has been estimated that 75%-85% of ER+ (estrogen receptor-positive) and PR+ (progesterone receptor-positive) patients are likely to respond to hormone therapy, whereas those with ER− and PR− tumors are not likely to respond to endocrine therapy.3,5 ER status also predicts benefit from second-line and subsequent hormone therapy. ER/PR status, therefore, represents an important intermediate end point that predicts both prognosis and response to treatment.7 On the other hand, HER2 is expressed in
approximately 15%-20% of high-grade invasive breast cancers and is associated with rapid tumor growth, increased risk of recurrence after surgery, poor response to nontargeted therapy (chemotherapy), and shortened survival.8

The prevalence of ER/PR/HER2 and the distribution of surrogate molecular subtypes of breast cancer vary considerably between racial/ethnic groups.9 In the Middle East, initial studies have shown that Arabic women are more likely to be diagnosed with tumors that are negative for ER/PR receptors compared with their western (Western European/American) counterparts.9-15 However, recently, similar studies conducted on Arabic patients with breast cancer reported ER/PR expression rates that are comparable with those of female populations in the West.16-23

In this study, our primary objective is to examine whether the expression rates of ER/PR and HER2 in Jordanian breast cancer significantly differed from the rates previously published by Sughayer et al10 and investigate the factors that might have influenced the disparity.

MATERIALS AND METHODS

Clinicopathologic data of a cohort of 1,185 Jordanian patients with breast cancer diagnosed in 2018 were collected from the archives of the Department of Pathology at the King Hussein Cancer Center. Histopathologic records were reviewed for patients’ age, histologic type of breast carcinoma, grade of carcinoma, hormone receptors (HRs), and HER2 status. The archived specimens included in this study were all originally received as either surgical specimens fixed in 10% buffered formalin or as paraffin-embedded blocks. The breast carcinomas were classified according to WHO classification of breast tumors into invasive carcinoma of no special type (NST), lobular, or other types. The HR and HER2 status was determined using either immunohistochemical methods (IHC) alone (for ER and PR) or IHC and fluorescence in situ hybridization for equivocal HER2 cases (cases scored as 2+).

It is worth mentioning that we used unpublished data from our previously published study10 for comparison of triple-negative breast cancer (TNBC) numbers. The Institutional Review Board at the King Hussein Cancer Center approved collection of the data presented in this article and its publication (No. 20 KHCC 30).

Immunostaining

Immunostaining was performed using the Ventana 1E2 antibody clone for PR (rabbit monoclonal primary antibody, prediluted; Ventana Medical Systems, Tucson, AZ), Ventana SP1 antibody clone for ER (rabbit monoclonal primary antibody, prediluted; Ventana Medical Systems), and Ventana Pathway (4B5) antibody clone for HER2 (rabbit monoclonal primary antibody, prediluted; Ventana Medical Systems) as per the manufacturer’s instructions and run on the Ventana Benchmark Ultra system using the OptiView detection system. Positive controls were included on the same slide for each immune stain. Immunoreactivity was evaluated by two pathologists separately using the College of American Pathologists/ASCO 2010 guidelines for ER/PR and 2013 for HER2.24,25 Evaluation of HER2 by fluorescence in situ hybridization was performed in the IHC equivocal cases (2+) using a commercially available kit (Path Vysion; Vysis Inc, Downers Grove, IL).

Approximation of Molecular Subtypes

Approximation of the molecular subtypes on the basis of the ER/PR/HER2 status was adopted from the 13th St Gallen consensus,26 however, with minor changes because of the lack of the Ki-67 marker for most cases. Another adaptation was the inclusion of low ER/PR (< 10%) as a criterion for the luminal B (HER2–) subtype. Cases were classified as follows:

1. Luminal A: if both (ER and PR)+ and HER2–.
2. Luminal B (HER2+) [human epidermal growth factor receptor 2-positive]: if ER or PR+ and HER2+ or luminal B (HER2– [human epidermal growth factor receptor 2-negative]) if HER2– and either ER or PR is low positive (< 10%) or negative (but not both negative).
Changes in ER/PR/HER2 Overtime in Breast Cancer in Jordan

**TABLE 1.** Distribution of ER/PR/HER2 in Breast Cancer Types

| Feature         | Invasive Carcinoma of NST, No. (%) | Lobular Carcinoma, No. (%) | Other Types, No. (%) | Total, No. (%) |
|-----------------|------------------------------------|-----------------------------|----------------------|---------------|
| ER+             | 670 (77.2)                         | 81 (96.4)                   | 161 (69.1)           | 912 (77.0)    |
| PR+             | 634 (73.0)                         | 74 (88.1)                   | 150 (64.4)           | 858 (72.4)    |
| HER2+           | 225 (25.9)                         | 3 (3.6)                     | 53 (22.8)            | 281 (23.7)    |
| ER or PR+       | 708 (81.7)                         | 81 (96.4)                   | 182 (78.1)           | 974 (82.2)    |
| TPBC            | 110 (12.7)                         | 2 (2.4)                     | 19 (8.2)             | 131 (11.1)    |
| Low ER/PR       | 87 (10.0)                          | 7 (8.3)                     | 28 (12.0)            | 122 (10.3)    |
| TNBC            | 86 (9.9)                           | 2 (2.4)                     | 32 (13.7)            | 120 (10.1)    |

Of the total cases, 868 (73.3%) were found to be ER/PR-positive, 84 (7.1%) were ER-negative, and 233 (19.7%) had other subtypes. The distribution of HER2+ was 110 (12.7%) for invasive carcinoma, 2 (2.4%) for lobular carcinoma, and 2 (2.4%) for other subtypes. The TPBC cases were 110 (12.7%), low ER/PR cases were 87 (10.0%), and TNBC cases were 86 (9.9%)

**TABLE 2.** Approximation of Molecular Subtypes of Breast Carcinoma

| Molecular Subtype | Invasive Carcinoma of NST, No. (%) | Lobular Carcinoma, No. (%) | Other Variants/Subtypes, No. (%) | Total, No. (%) |
|-------------------|------------------------------------|-----------------------------|----------------------------------|---------------|
| Luminal A         | 445 (51.3)                         | 65 (77.4)                   | 92 (39.5)                        | 602 (50.8)    |
| Luminal B (HER2+) | 152 (17.5)                         | 3 (3.6)                     | 36 (15.5)                        | 191 (16.1)    |
| Luminal B (HER2−) | 112 (12.9)                         | 14 (16.7)                   | 56 (24.0)                        | 182 (15.4)    |
| HER2-enriched     | 73 (8.4)                           | 0 (0.0)                     | 17 (7.3)                         | 90 (7.6)      |
| TNBC              | 86 (9.9)                           | 2 (2.4)                     | 32 (13.7)                        | 120 (10.1)    |

Total 868 84 233 1,185

Abbreviations: HER2, human epidermal growth factor receptor 2; HER2+, human epidermal growth factor receptor 2-positive; HER2−, human epidermal growth factor receptor 2-negative; NST, no special type; TNBC, triple-negative breast cancer.

3. HER2-enriched: if only HER2 is positive
4. TNBC if each of ER, PR, and HER2 are negative
In addition, a fifth category was added.
1. Triple-positive breast cancer if ER, PR, and HER2 are all positive

**Statistical Handling**
Descriptive statistics were used to describe the findings. In addition, chi-square and Student’s t-tests were used to compare sets of data. A P value of ≤ .05 was considered to be statistically significant.

**RESULTS**
**ER/PR/HER2 in Various Types**
Patients’ age ranged between 26 and 93 years (median = 51, mean = 52.0 years), with 528 (44.67%) patients being age < 50 years. Of the total, 868 (73.2%) of the cases were invasive carcinoma of NST of various histologic grades, 670 (77.2%) of which were ER+, 634 (73.0%) PR+, 225 (25.9%) HER2+, and 86 (9.9%) triple-negative. On the other hand, lobular carcinomas were observed in 84 (7.1%) of all cases, 81 (96.4%) of which were ER+, 74 (88.1%) PR+, 3 (3.6%) HER2+, and two (2.4%) triple-negative (Table 1).

As expected, the rates of ER, PR, and HER2 expression were statistically significantly different between the invasive carcinoma of NST and the lobular types where more of the lobular were likely to be ER+/PR+ (P value ≤ .0001 and .0016, respectively) and less likely to be HER2+ (P value ≤ .0001).

**Approximating Molecular Subtypes**
Approximating the molecular subtypes on the basis of IHC is shown in Table 2. Around 50% of all cases were luminal A, whereas luminal B ranged from 21% to 40% depending on the histologic subtype. Most of the lobular carcinomas (78%) were luminal A. The HER2-enriched and TNBC subtypes in the entire cohort were approximately 8% and 10%, respectively.

Other types of breast carcinomas (including mixed type, mucinous, micropapillary, apocrine, tubular, cribriform, and metaplastic carcinoma) constituted 233 cases (19.7%), of which 32 (13.7%) were triple-negative and 161 (69.1%), 150 (64.4%), and 53 (22.8%) were ER+, PR+, and HER2+, respectively.

Of the total cases, 33 (2.8%) had low ER expression (1%-9%), whereas those with the low PR (1%-9%) were 89 (7.5%). In total, the number of cases with low expression of both ER and PR HRs status was 4 (0.3%).

Of the entire group, the number of triple-positive cases was 131 (11.1%). These overlap with (are part of) the luminal B HER2+ group, which is around 16%.

**Comparison With the Previous Study**
Table 3 displays comparison between the current study and the 2006 study in terms of the rates of HR and HER2
positivity in each of the invasive carcinomas of NST and lobular carcinoma. The rates are significantly higher in the current study for all three markers in the invasive carcinoma of NST subtype (P value for ER+/PR+ < .001, and for HER2+ .006) and significantly higher only for ER (P value < .001) in the lobular type. The TNBC rate was much less in the invasive carcinoma of NST in the current study than the previous one. Assuming that the cutoff for the ER and PR positivity was 10% in the previous study, which is now 1%, the difference will still be significant for all three markers in the invasive carcinoma of NST and the ER in the lobular type.

**Age**

Patients older than 50 years had higher percentages of ER+ and HER2+ cases than patients who are younger than 50 years; however, this association was not significant (P value = .47; Table 4).

**DISCUSSION**

Breast malignancies have significant differences in ER/PR expression and HER2 status around the world with regard to race and ethnicity. The causes of these differences are likely to be multifactorial including socioeconomical factors and biologic differences reflected from genetic influences and differences in lifestyle, nutrition, or environmental exposure.27

This study consisted of 1,185 patients with breast cancer, which, to our knowledge, is the largest cohort for a study of this type in the Middle East.

The present work comes as an update study to a previously published one by the same group10 and conducted in the same cancer facility, King Hussein Cancer Center, which treats 70%-80% of Jordanian patients with breast cancer. The aim was to re-evaluate the prevalence of the ER/PR and HER2 status in the Jordanian population, given the current changes in socioeconomic status, changes in lifestyle and nutrition, and advancements in diagnostic techniques.

The average age for this cohort was 52 years (median = 51 years, range = 25-92 years), which is considered quite young compared with the mean age upon diagnosis in American populations as reported by Parise et al (mean = 59 years) and by Jiagge et al who reported a mean age at diagnosis of 60 and 62 years for African and White Americans, respectively.9,28 However, the age reported in Jordan is comparable with other countries in the same region or in the same income category: Peru (mean = 50.5)17 and Egypt (mean = 49.5),22 and close to some European countries such as Poland where the mean age of luminal A and B subtypes is 56.3 years.29

ER, PR, and HER2 are important predictive and prognostic biomarkers that can be used to approximate the molecular subtypes. Studies conducted over the past few years

### TABLE 3. Comparison Between the Current Study and the 2006 Cohort

| Feature          | Invasive Carcinoma of NST | Lobular Carcinoma |
|------------------|---------------------------|-------------------|
|                  | Current Study, No. (%)    | 2006 Cohort, No. (%) | P     | Current Study, No. (%)    | 2006 Cohort, No. (%) | P     |
| ER+              | 670 (77.2)                | 122 (50.8)        | < .001 | 81 (96.4)                | 15 (68.2)           | < .001 |
| PR+              | 634 (73.0)                | 138 (57.5)        | < .001 | 74 (88.1)                | 20 (90.8)           | .71   |
| HER2+            | 225 (25.9)                | 42 (17.5)         | .006   | 4 (4.8)                  | 3 (13.6)            | .14   |
| TNBC             | 86 (9.9)                  | 50 (21.0)         | < .001 | 2 (2.4)                  | 1 (4.5)             | .58   |
| Total            | 686                       | 240               |        | 84                       | 22                  |       |

**Abbreviations:** ER+, estrogen receptor-positive; HER2+, human epidermal growth factor receptor 2-positive; NST, no special type; PR+, progesterone receptor-positive; TNBC, triple-negative breast cancer.

### TABLE 4. Comparison of ER/PR/HER2 Between Patients on the Basis of Age

| Subtype                      | ER+, No. (%) | PR+, No. (%) | HER2+, No. (%) | Low ER/PR, No. (%) | TNBC, No. (%) |
|------------------------------|--------------|--------------|----------------|-------------------|---------------|
| **Age < 50 Years**           |              |              |                |                   |               |
| Total                        | 528          | 397 (75.19)  | 386 (73.11)    | 135 (25.57)       | 47 (8.90)     | 63 (11.93)   |
| Invasive carcinoma of NST     | 403          | 308 (76.43)  | 303 (75.19)    | 114 (28.29)       | 33 (8.19)     | 43 (11.93)   |
| Lobular carcinoma             | 27           | 27 (100.00)  | 26 (96.30)     | 0 (0.00)          | 2 (7.41)      | 0 (0.00)     |
| **Age ≥ 50 Years**            |              |              |                |                   |               |
| Total                        | 657          | 515 (78.40)  | 472 (71.84)    | 146 (31.40)       | 75 (11.42)    | 57 (8.68)    |
| Invasive carcinoma of NST     | 465          | 362 (77.90)  | 331 (71.18)    | 111 (23.87)       | 54 (11.61)    | 43 (9.25)    |
| Lobular carcinoma             | 57           | 54 (94.74)   | 48 (84.21)     | 3 (5.26)          | 5 (8.77)      | 2 (3.51)     |

**Abbreviations:** ER, estrogen receptor; ER+, estrogen receptor-positive; HER2+, human epidermal growth factor receptor 2-positive; NST, no special type; PR, progesterone receptor; PR+, progesterone receptor-positive; TNBC, triple-negative breast cancer.
reported a wide range of proportion of patients expressing these markers. This disparity is usually largely attributed to racial/ethnic differences.29-35

The most prominent breast cancer histologic subtype in our current cohort is invasive carcinoma of NST (73.3%) followed by other variants of breast cancer types (19.7%). On the other hand, the most frequent molecular subtype in this study is luminal A (50.8%) followed by luminal B HER2+ (16.1%), and the least common subtype is HER2-enriched (7.6%).

In addition, ER/PR and HER2 rates for the patients in the current study were considerably higher than the percentages published in a previous study by the same group in 2006 (Tables 3 and 5). Both studies were conducted in the same institute, and IHC evaluation was also performed by the same group of pathologists; that being said, the deployed methods (manual vs automated), detection methods, and primary antibody clones were different (Table 6). In 2009, the laboratory became College of American Pathologists–accredited and has since participated in External Quality Assessment Systems/proficiency testing programs that cover immunohistochemical predictive biomarker testing.

In regard to the antibody clones/assays used, it has been shown that the currently used antibodies/assays for ER/PR/HER2 in our study are more sensitive than those used in the previous study and so tend to yield more positive results. These studies have shown that the SP1 antibody clone for ER used in our current study (Table 6) is more sensitive than 1D5 used previously.38,39 Also, other studies have demonstrated differences and similarities between different antibody clones and assays for ER/PR and HER2.40 For the latter, the Ventana Pathway assay for HER2 appears to be more sensitive than the Dako HercepTest that we used in our study. Another point concerning the IHC methodology is the manual versus automated techniques used where it is thought that automated methods are likely to be more sensitive and specific although some studies showed that this is not necessarily true.

Nevertheless, the difference in the rates between the two studies is greater than that would be anticipated on the basis of technical reasons alone, especially considering that this trend of change in the biomarker rates is observed among similar Middle Eastern cohorts (Table 5). Therefore, other factors are more likely to be involved in the causation of this trend, which may also be applicable to other countries in the Middle East. Hence, we propose that adoption of a more westernized lifestyle by women in our region, more exposure to industrial estrogens, and increase in the life expectancy among women, which may play a role in the increase of ER+/PR+ cancers among older women, are among those factors leading to improved socioeconomic status and the observed trend of change.

We propose that the improved socioeconomic factors are directly related to the adoption of westernized lifestyle as

| Feature | Jordan Current Study, % | Sughayer et al, 2006, % | Egypt Alad et al, 2014, % | Dey et al, 2010, % | Saudi Arabia Khabaz, 2014, % | Amr et al, 2019, % | Lebanon El Saghir et al, 2014, % | Abadjian, 1996, % |
|---------|-------------------------|-------------------------|--------------------------|-------------------|---------------------|-----------------|-------------------------|------------------|
| ER+     | 76.96                   | 50.8                    | 73                       | 68.9              | 75.50               | 42.9            | 74.40                   | 43               |
| PR+     | 72.41                   | 57.50                   | 63                       | 58.1              | 38.1                | 69              | 23.80                   | 65               |
| HER2+   | 23.80                   | 17.50                   | 37                       | NA                | 32                  | NA              | 23.80                   | 65               |

Abbreviations: ER+, estrogen receptor-positive; HER2+, human epidermal growth factor receptor 2-positive; NA, not applicable; PR+, progesterone receptor-positive.

| Technical Feature | Jordan—2018 (current study) | Jordan—2006 (study by Sughayer et al) |
|-------------------|-----------------------------|---------------------------------------|
| Detection method  | Ventana Benchmark Ultra system using the OptiView detection system | Avidin-biotin-peroxidase manual method |
| Primary antibody clone | PR: Ventana 1E2 antibody clone (rabbit monoclonal primary PR antibody, prediluted; Ventana Medical Systems, Tucson, AZ) | PR: Monoclonal Mouse Anti-Human PR, clone PR 636 |
|                   | ER: Ventana SP1 antibody clone (rabbit monoclonal primary ER antibody, prediluted; Ventana Medical Systems, Tucson, AZ) | ER: Monoclonal Mouse Anti-Human ER clones 1D5 Dako company [Glostrup, Denmark] |
|                   | HER2: Ventana Pathway (4B5) antibody clone (rabbit monoclonal primary HER2 antibody, prediluted; Ventana Medical Systems, Tucson, AZ) | HER2: HercepTest (rabbit polyclonal antibody; Dako company [Glostrup, Denmark]) |
| EQAS              | CAP                         | None                                  |

Abbreviations: CAP, College of American Pathologists; EQAS, External Quality Assessment Systems; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor.
manifested by the dramatic rise in obesity rates related to changes in dietary habits associated with the introduction of nontraditional high-fat foods and decreased fertility rates, and the increased age at first pregnancy might have contributed to the changes in the prevalence of hormonal receptors in breast cancer among Jordanian women. Reproductive factors and risk of ER+/PR+ breast cancers are previously documented.

The observed rates in this study are comparable with the percentages found in studies of Western White cohorts and similar to those published by Middle Eastern scholars in recent years. The current proportion of HR+ cases in Jordan (82.9%) is very close to that in United States, which is 84%-85%. Similarly, the TNBC in Jordan proportion is currently at 10.1% comparable with 11.4% in the United States. The only difference is in the HER2, which is 23.8% in Jordan compared with 15.5% in the United States.

However, the proportion of cases expressing HRs and HER2 is lower in patients from African and/or Hispanic descents compared with their non-Hispanic White counterparts. Looking back at studies recently conducted in the United States and Canada, we see that although a racial disparity is still pronounced, the rate of expression is much higher in the groups living in the United States and Canada than the reported percentages from less-developed countries in Africa, Asia, and the southern American continent. These findings support the aforementioned argument that the adoption of a westernized lifestyle by our emerging communities, increased life expectancy, and exposure to exogenous estrogens are more likely responsible factors than others in explaining this trend. This is by no means intended to underestimate the genetic predisposition of certain ethnic groups for some types of breast cancer such as TNBC and the role of improved IHC techniques and different antibody clones in increasing the sensitivity and therefore detection rates of ER/PR/HER2.

In conclusion, a significant increase in the rates of ER, PR, and HER2 is observed over a period of 15 years (first cohort from 2003 to 2004 and the current one from 2018). Apart from the improved detection techniques, the reasons for this change are not entirely clear in this study. This change may be secondary to multiple factors, with adoption of a more westernized lifestyle by Jordanian women probably being a major player.

Nevertheless, further epidemiologic and socioeconomic studies discussing these associations in the Middle Eastern population are warranted.

REFERENCES

1. Abdel-Razeq H, Mansour A, Jaddan D: Breast cancer care in Jordan. JCO Glob Oncol 6:260-268, 2020
2. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018
3. Riva C, Dainese E, Caprara G, et al: Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Archiv 447:695-700, 2005
4. Hussein IA, Ahmed ST, Hameedi AD, et al: Immunohistochemical expression of BRCA1 protein, ER, PR and HER2 in breast cancer: A clinicopathological study. Asian Pac J Cancer Prev 21:1025-1029, 2020
5. Dai X, Xiang L, Li T, et al: Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer 7:1281-1294, 2016
6. Rauscher GH, Campbell RT, Wiley EL, et al: Mediation of racial and ethnic disparities in estrogen/progesterone receptor-negative breast cancer by socioeconomic position and reproductive factors. Am J Epidemiol 183:884-893, 2016

AFFILIATIONS

1. King Hussein Cancer Center, Amman, Jordan
2. Hashemite University, Zarqa, Jordan

CORRESPONDING AUTHOR

Maher A. Sughayer MD, Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman 11941, Jordan; Twitter: @MaherSughayer; e-mail: msughayer@khcc.jo.

AUTHOR CONTRIBUTIONS

Conception and design: Anas M. Alsughayer, Tamara Z. Dabbagh, Ghada N. Al-Jussani, Maher A Sughayer
Collection and assembly of data: Anas M. Alsughayer, Rashid H. Abdel-Razeq, Ghada N. Al-Jussani, Salam Alhassoon, Maher A Sughayer
Data analysis and interpretation: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

No potential conflicts of interest were reported.
7. Bardou VJ, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973-1979, 2003

8. Masmoudi H, Hewitt SM, Petrick N, et al: Automated quantitative assessment of HER-2/neu immunohistochemical expression in breast cancer. IEEE Trans Med Imaging 28:916-925, 2009

9. Parise CA, Caggiano V: The influence of socioeconomic status on racial/ethnic disparities among the ER/PR/HER2 breast cancer subtypes. J Cancer Epidemiol 2015:815456, 2015

10. Sughayer MA, Al-Khawaja MM, Massanwes S, et al: Prevalence of hormone receptors and HER2 in breast cancer cases in Jordan. Pathol Oncol Res 12:83-86, 2006

11. Khader H, Salem B, Omar AS, et al: Prevalence of hormonal receptors ER, PR and HER-2/neu in breast cancer cases in Palestine. Pan Arq J Oncol 2:28-31, 2009

12. Alisherawy HA: Prevalence of androgen receptors in invasive breast carcinoma and its relation with estrogen receptor, progesterone receptor and HER2 expression. J Egypt Natl Cancer Inst 24:77-83, 2012

13. Amr SS, Sa’di AR, Ilahi F, et al: The spectrum of breast diseases in Saudi Arab females: A 26 year pathological survey at Dhahran Health Center. Ann Saudi Med 15:125-132, 1995

14. Abadjan G, Antoun R: Breast carcinoma: Evaluation of hormone receptors and p53, erb-B2, P-glycoprotein and Ki-67 markers [in French]. J Med Liban 44:10-15, 1996

15. Dey S, Soliman AS, Hablas A, et al: Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt. Breast Cancer Res Treat 120:149-160, 2010

16. Sengal AT, Haj Mukhtar NS, Vetter M, et al: Comparison of receptor-defined breast cancer subtypes between German and Sudanese women: A facility-based cohort study. J Glob Oncol 4:1-2, 2017

17. Vallezos CS, Gomes HL, Cruz WR, et al: Breast cancer classification according to immunohistochemistry markers: Subtypes and association with clinicopathologic variables in a Peruvian hospital database. Clin Breast Cancer 10:294-300, 2010

18. Kallel I, Khairi A, Boujebene N, et al: EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia. J Recept Signal Transduct Res 3:142-149, 2012

19. El Saghir NS, Assi HA, Jaber SM, et al: Outcome of breast cancer patients treated outside of clinical trials. J Cancer 5:491-498, 2014

20. Runnak MA, Hazha MA, Hemin HA, et al: A population based study of Kurdish breast cancer in Northern Iraq: Hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data. BMC Womens Health 12:16-25, 2012

21. Khabaz MN: Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: Where do we stand in the West of Saudi Arabia? Asian Pac J Cancer Prev 15:8395-8400, 2014

22. Aiad HA, Wahed MM, Asaad NY, et al: Immunohistochemical expression of QPR30 in breast carcinoma of Egyptian patients: An association with immunohistochemical subtypes. APMIS 122:976-984, 2014

23. Al Tamimi DM, Shawarby MA, Ahmed A, et al: Protein expression profile and prevalence pattern of the molecular classes of breast cancer—A Saudi population based study. BMC Cancer 10:223, 2010

24. Hammond MEH, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guidelines for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010

25. Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3897-4013, 2013

26. Goldenhirsch A, Winer EP, Coates AS, et al: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206-2223, 2013

27. Kurebayashi J, Moriya T, Ishida T, et al: The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16:72-77, 2007

28. Jiagg E, Jibril AS, Chitala D, et al: Comparative analysis of breast cancer phenotypes in African American, White American, and West versus East African patients: Correlation between African ancestry and triple-negative breast cancer. Ann Surg Oncol 23:3843-3849, 2016

29. Khaled H, Salem B, Omar AS, et al: Prevalence of hormonal receptors ER, PR and HER-2neu in breast cancer cases in Palestine. J Pak Med Assoc 65:747-752, 2015

30. Thabet AH, El Khayat SF, Zayed MA, et al: Prevalence of hormone receptors ER, PR and HER-2 in breast cancer cases in Jordan. J Cancer 5:491-498, 2014

31. Rauscher GH, Silva A, Pauls H, et al: Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: Implications for reducing breast cancer mortality disparities. Breast Cancer Res Treat 163:321-330, 2017

32. Wan D, Villa D, Woods R, et al: Breast cancer subtype variation by race and ethnicity in a diverse population in British Columbia. Clin Breast Cancer 16:e49-e55, 2016

33. Pervaiz F, Rehmani S, Majid S, et al: Evaluation of hormone receptor status (ER/PR/HER2-neu) in breast cancer in Pakistan. J Pak Med Assoc 65:747-752, 2015

34. Clarke CA, Keegan TH, Yang J, et al: Age-specific incidence of breast cancer subtypes: Understanding the black–white crossover. J Natl Cancer Inst 104:1094-1101, 2012

35. Yaqub H, Bhatla A, Chauhan P, et al: HER2 status and relation to clinicopathological factors in breast carcinoma. Int J Pharm Pharm Sci 8:287-290, 2016

36. Bae Y, Song S, Kang J, et al: Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: A multi-institutional retrospective study using tissue microarrays. Am J Surg Pathol 38:1817-1825, 2012

37. Amr SS, Sa’di AR, Ilahi F, et al: The spectrum of breast diseases in Saudi Arab females: A 26 year pathological survey at Dhahran Health Center. Ann Saudi Med 15:125-132, 1995

38. Bae YK, Gong G, Kang J, et al: Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: A multi-institutional retrospective study using tissue microarrays. Am J Surg Pathol 36:1817-1825, 2012

39. Troxell ML, Long T, Hornick JL, et al: Comparison of estrogen and progesterone receptor antibody reagents using proficiency testing data. Arch Pathol Lab Med 141:1402-1412, 2017

40. HER2 IHC—NordiQC. 2018. HercepTest™ (Dako) and PATHWAY® (Ventana), in NordiQC reference laboratories. https://www.nordiqc.org/downloads/assessments/148_11.pdf

41. Khader Y, Batheh A, Aljoumi H, et al: Obesity in Jordan: Prevalence, associated factors, comorbidities, and change in prevalence over ten years. Metab Syndr Relat Disord 6:113-120, 2008

42. Aljoumi H, Khader Y, Batheh A, et al: An alarmingly high and increasing prevalence of obesity in Jordan. Epidemiol Health 42:e2020040, 2020

43. Kraft C, Kula E, Sieverding M: An investigation of Jordan’s fertility stall and resumed decline: The role of proximate determinants. Demographic Res 45:605-652, 2021
44. Ma H, Bernstein L, Pike MC, et al: Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: A meta-analysis of epidemiological studies. Breast Cancer Res 8:R43, 2006
45. Gong Y, Liu Y-R, Ji P, et al: Impact of molecular subtypes on metastatic breast cancer patients: A SEER population-based study. Sci Rep 7:45411, 2017
46. Kong X, Liu Z, Cheng R, et al: Variation in breast cancer subtype incidence and distribution by race/ethnicity in the United States from 2010 to 2015. JAMA Netw Open 3:e2020303, 2020